Head-To-Head Analysis: Argos Therapeutics (OTCMKTS:ARGSQ) vs. AEON Biopharma (NASDAQ:AEON)

AEON Biopharma (NASDAQ:AEON) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Profitability

This table compares AEON Biopharma and Argos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Argos Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares AEON Biopharma and Argos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.10
Argos Therapeutics	$1.90 million	0.30	-$40.57 million	N/A	N/A

AEON Biopharma has higher earnings, but lower revenue than Argos Therapeutics.

Risk & Volatility

AEON Biopharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for AEON Biopharma and Argos Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Argos Therapeutics	0	0	0	0	0.00

Insider & Institutional Ownership

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

AEON Biopharma beats Argos Therapeutics on 5 of the 9 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Argos Therapeutics

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.